The Impact of Right Ventricular Dysfunction on the Mortality in Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis.

Ryota Sato  
Cleveland Clinic Foundation: Cleveland Clinic

Siddharth Dugar (dugars@ccf.org)  
Cleveland Clinic Foundation: Cleveland Clinic  https://orcid.org/0000-0002-3243-1417

Wisit Cheungpasitporn  
Mayo Clinic Rochester: Mayo Clinic Minnesota

Mary Schleicher  
Cleveland Clinic Alumni Library: Cleveland Clinic

Patrick Collier  
Cleveland Clinic Foundation: Cleveland Clinic

Saraschandra Vallabhajosyula  
Emory University School of Medicine

Abhijit Duggal  
Cleveland Clinic Foundation: Cleveland Clinic

Research

Keywords: right ventricular dysfunction, acute cor pulmonale, acute respiratory distress syndrome, acute lung injury

DOI: https://doi.org/10.21203/rs.3.rs-291532/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Previous studies have found various incidences of right ventricular dysfunction (RVD) and its association with clinical outcome. In this systematic review and meta-analysis, we aimed to investigate the impact of the presence of RVD on mortality in patients with ARDS.

Method: We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials for studies investigating the association between RVD and mortality. Two authors independently evaluated whether studies meet eligibility criteria and extracted the selected patients' and studies' characteristics and outcomes. The primary outcome was the association between mortality and the presence of RVD in patients with ARDS.

Results: We included 9 studies (N = 1,861 patients) in this meta-analysis. RVD was present in 21.0% (391/1,861). In the pooled meta-analysis, the presence of RVD in patients with ARDS was associated with significantly higher overall mortality (OR: 1.45, 95%CI: 1.13-1.86, p-value = 0.003, I² = 0%), as well as short-term mortality (OR: 1.48, 95%CI: 1.14-1.93, p-value = 0.003, I² = 0%).

Conclusion: In this systematic review and meta-analysis including 1,861 patients with ARDS, the presence of RVD was significantly associated with increased overall and short-term mortality.

Trial registration: The protocol was registered at PROSPERO (CRD42020206521).

Background

Despite advances in the management of ARDS including lung-protective ventilation, prone positioning, and neuromuscular blockade, the mortality still remains alarmingly high, with a recent meta-analysis reporting a mortality of 30–40%. [1] There is evolving evidence that right ventricular dysfunction (RVD) with associated hemodynamic compromise might be a significant factor associated with higher mortality in ARDS. [2]

The etiology of RVD in patients with ARDS is complex and is driven primarily by an increase in pulmonary vascular resistance due to ongoing inflammation, hypoxemia driven vasoconstriction, micro-thrombi formation, and vascular remodeling. [3] The thin-walled right ventricle with a low contractile reserve is ill-adapted for an abrupt increase in afterload, and this leads to acute cor-pulmonale in these patients. RVD is further exacerbated with the use of positive pressure ventilation in patients with ARDS due to increased RV afterload from increased intrathoracic pressure. [4]

Historically, pulmonary artery catheters were used to evaluate right heart function in ARDS patients, however, contemporary intensive care units (ICU) rarely use pulmonary artery catheters in routine practice. [5] The widespread usage of critical care echocardiography in recent times has renewed interest in better understanding not only the prognostic role of RVD in mortality associated with ARDS but also the factors associated with RVD. [2] Previous studies have reported a wide range of the prevalence of RVD in ARDS. Also, most of these studies had small sample sizes and varying methodologies which led to discordant results. In this systematic review and meta-analysis, we aim to pool these studies to better understand the prevalence of RVD and to report on the mortality in patients with ARDS who develop RVD.

Methods

Data Sources and Search Strategy

This study complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement, [6, 7] and the Meta-Analyses of Observational Studies in Epidemiology proposals. [8] Our protocol was registered at PROSPERO (CRD42020206521).

A comprehensive search of Medline, Embase, and Cochrane Central Register of Controlled Trials was conducted with the search strategy detailed in Supplementary Table 1. The search period was limited from 1990 to 2020. Our search was updated on August 28, 2020. We stored citations and removed duplicates using EndNote (Thomson Reuters, Toronto, Ontario, Canada). Two reviewers (R.S. and S.D.) independently reviewed the titles and abstracts obtained by the search and selected those that fit the inclusion criteria. We then retrieved these articles, independently read the full-text, and evaluated whether the articles fit our inclusion criteria on Covidence (https://www.covidence.org).

When there were disagreements between the two reviewers, it was discussed with the third reviewer (S.V.) in detail to reach a consensus. Two authors (R.S. and S.D.) independently extracted the following data from the eligible studies: year of publication, country, number of participants, mean/median age, sex, the definition of RVD, cause of ARDS, the mortality, and inclusion and exclusion criteria.

Inclusion And Exclusion Criteria

We included interventional and observational studies that focused on the association between RVD and the mortality in patients (≥ 18 years old) with ARDS. Studies assessing RV structure and function with either transthoracic or transesophageal echocardiography (TTE or TEE), or pulmonary artery catheterization were included. ARDS was diagnosed based on either American European consensus conference or Berlin definition. [10] We excluded studies where a 2 X 2 table between RV function and mortality cannot be constructed, conference proceedings (due to high risk of bias), and studies from non-English literature. If studies had duplication of data, and the same data was published at different time points, we chose the most relevant study as the representative sample for this meta-analysis.

The primary outcome for this study was the overall reported mortality defined as either the intensive care unit (ICU) mortality, in-hospital mortality, or mortality within 90 days. We also performed the pooled analysis for short-term mortality (ICU-mortality, in-hospital mortality, or mortality ≤ 30 days) and long-term mortality. 

mortality (>30 days), as well as the pooled analysis for adjusted odds ratio for the mortality.

**Statistical analysis**

The pooled odds ratios (ORs) and 95% confidence intervals (CI) were calculated using the random effect (DerSimonian-Laird) method [11] Q statistic test, as well as $I^2$ statistic with 95% CI, were used to assess heterogeneity. For Q statistic, substantial heterogeneity was defined as $p < 0.05$. The $I^2$ statistic ranges from 0 to 100% ($I^2 < 25%$: low heterogeneity, $I^2 = 25–50%$: moderate heterogeneity, and $I^2 > 50%$: substantial heterogeneity). [12]

To assess publication bias, we created the funnel plots and tested the symmetry of the funnel plots using Egger's regression test. [13]

Statistical analysis was performed using Comprehensive Meta-analysis version 3 software (Biostat Inc, Eaglewood, MJ, USA) and Review Manager (RevMan) 5.4.1 software (Cochrane Information Management System).

**Assessment Of The Risk Of Bias**

The risks of bias were independently evaluated by two authors (R.S. and S.D.) and verified by another author (S.V.). If there were disagreements, a discussion with the research team was held to reach a consensus. We assessed the study quality of each article using the quality of the study using a modified version of the Newcastle-Ottawa quality assessment scale. [14]

**Results**

**Search results**

Our search strategy identified 2,307 articles. After removing the duplicates and clearly irrelevant studies, full texts of 103 studies were assessed for eligibility. Fourteen studies reported the outcomes of interest for RVD in patients with ARDS. [15–28] Nine studies with a total of 1,861 patients were included for the final analysis as shown in Fig. 1. [16, 19–21, 23, 24, 26–28]

**Baseline Characteristics**

All articles were published between 2009 and 2018. Six studies were conducted in Europe, [16, 19–21, 23, 28] one in the United States, [27] and two in Asia, [24, 26]. Five were prospective observational studies, [20, 21, 24, 26, 28] two were retrospective studies, [16, 19] and two were the post-hoc analysis of a previously conducted randomized controlled trial, [23, 27] (Table 1) Inclusion and exclusion criteria for the studies are shown in Supplementary Table 2. The risk of bias for the included studies was evaluated using a modified version of the Newcastle-Ottawa Scale, as shown in Table 3.
| Authors | Country   | Sample size | Setting                      | Study period       | Definition of ARDS                                         | Definition of RVD                                             | Mortality  |
|---------|-----------|-------------|------------------------------|--------------------|-----------------------------------------------------------|--------------------------------------------------------------|------------|
| Osman / 2009 | France | 145         | Multi-center, post-hoc analysis of RCT | January 1999 – June 2001 | American-European consensus conference | (1) MPAP > 25 mmHg, (2) CVP > PAOP and (3) SVI < 30 mL/m², based on PAC. | 28-day     |
| Bull / 2010 | United States | 367 | Post-hoc analysis of multicenter randomized controlled trial | June 2000 – Oct 2005 | American-European consensus conference | CVP > PAOP | 60-day     |
| Fichet 2012 | France | 50          | Single-center, prospective | Not reported | American-European consensus conference | TAPSE < 12mm or St < 11.5cm/sec | ICU        |
| Legras / 2015 | France | 166         | Multi-center, prospective | November 2009 – June 2012 | American-European consensus conference | RVEDA/LVEDA ratio > 0.6 associated with systolic paradoxical ventricular septal motion by TTE or TEE. | 28-day     |
| Lazzeri / 2016 | Italy | 74          | Single-center, retrospective | October 2009 – December 2013 | Berlin definition. All included patients underwent VV-ECMO. | RVEDA/LVEDA ratio > 0.6 by TTE or TEE. | ICU        |
| Mekonstso Dessap / 2016 | France | 752         | Multi-center, prospective | 1994–2012 | Berlin definition (Although the study was initiated before 2011, all met the Berlin definition.) | RVEDA/LVEDA ratio > 0.6 associated with septal dyskinesia by TEE. | In-hospital |
| See / 2017 | Singapore | 234         | Single-center, prospective | September 2012 – May 2014 | Berlin definition | RVEDA/LVEDA ratio ≥ 1 by TTE. | In-hospital |
| Bonizzoli / 2018 | Italy | 28          | Single-center, retrospective | January 2016 – June 2017 | Berlin definition | RV strain free wall < 20%. | ICU        |
| Zeiton / 2018 | Egypt | 45          | Single-center, prospective | June 2016 – December 2016 | Berlin definition | RVEDA/LVEDA ratio > 0.6 associated with septal dyskinesia by TTE. | 28-day     |

RV: right ventricle / right ventricular
dysfunction

TAPSE: tricuspid annular plane systolic excursion

St: peak systolic velocity at the tricuspid valve

ACP: acute cor pulmonale

VV-ECMO: veno-venous extracorporeal membrane oxygenation

MPAP: mean pulmonary artery pressure

TTE: transthoracic echocardiography

TEE: transesophageal echocardiography

RCT: randomized controlled trial

PAC: pulmonary artery catheter

MPAP: mean pulmonary artery occlusion pressure

CVP: central venous pressure

PAOP: pulmonary artery occlusion pressure

SVI: stroke volume index
Table 2: The characteristics of included patients.

| Authors        | Age | Male (%) | Fluid in 24 hours (ml) | Vasopressors | Mechanical ventilation | P/F ratio | PEEP (cmH₂O) | Plateau pressure (cmH₂O) | Compliance (mL/cmH₂O) | LV function (mL/m²) |
|----------------|-----|----------|------------------------|--------------|------------------------|-----------|--------------|--------------------------|------------------------|----------------------|
| Osman /2009    | 64  | 35.7 % (5/14) | —                      | 78.6 % (11/14) | 100 % (14/14)          | 115 (26)  | 6 (4)        | 28 (6)                  | 23 (5)                  | SVI: 23 (3)          |
| RVD/ACP (+)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| RVD/ACP (-)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| Bull /2010     | 50  | 55.2 % (+) (262/475) | —                      | 36.4 % (+) (173/475) | 100% (+) (223/232)     | 160 †     | 9.3 †        | 26.2 †                  | —                      | Survived: Cl 4.5 (1.4) |
| RVD/ACP (+)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| RVD/ACP (-)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| Fichet /2012   | 60  | 67.9 % (19/28) | 4000 (3000–6000)       | 53% (8/15)   | 100% (28/28)           | 100       | 10           | 28                        | —                      | 49.5 (36–62)         |
| RVD/ACP (+)    | 51  | 50.0 % (9/18) | 4000 (2000–6000)       | 45% (16/35)  | 100% (18/18)           | 122       | 8            | 24                        | —                      | 63 (55–66)           |
| RVD/ACP (-)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| Legras /2015   | 56  | —        | —                      | 50.0 % (18/36) * | 100% (36/36) *       | 112 (91 = 154) | 10 (8–14) * | —                        | Cl: 2.9 (2.6–3.4) **   |                      |
| RVD/ACP (+)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| RVD/ACP (-)    |     |          |                        |              |                        |           |              |                          |                        |                      |
| Lazzeri /2016  | 57  | 70.6 % (20/29) | —                      | 64.7 % (11/17) | 100% (17/17)          | —         | —            | —                        | —                      | —                    |
| RVD/ACP (+)    | 50  | —        | —                      | 100% (26/57) |                          | —         | —            | —                        | —                      | —                    |
| RVD/ACP (-)    |     |          |                        |              |                        |           |              |                          |                        |                      |

*: The numbers were described for patients with only ACP or without ACP and PFO (Patients with only PFO or with PFO and ACP were excluded.

**: The value was reported as median with interquartile range.

***: The summation of each number did not fit the reported total number.

†: The standard deviation could not be calculated

† †: The numbers and percentages are per total population included in the study but not all patients were evaluated for RVD/ACP. Therefore, the total numbers actually analyzed number of patients.
| Authors                  | Age | Male (%) | Fluid in 24 hours (ml) | Vasopressors | Mechanical ventilation | P/F ratio | PEEP (cmH₂O) | Plateau pressure (cmH₂O) | Compliance (mL/cmH₂O) | LV function |
|-------------------------|-----|----------|------------------------|--------------|------------------------|-----------|--------------|--------------------------|-------------------------|--------------|
| Mekontso Dessap / 2016  |     |          |                        |              |                         |           |              |                          |                         |              |
| RVD/ACP (+)             | 57  | 63.4 % (104/164) | --                     | 68.9 % (113/164) | 100 % (164/164) | 106 (40) | 8 (4)        | 26 (5)                   | 28 (11)                  | --           |
| RVD/ACP (-)             | 58  | 68.5 % (403/588) | --                     | 66.2 % (389/588) | 100 % (588/588) | 118 (42) | 8 (4)        | 24 (4)                   | 32 (12)                  | --           |
| See / 2017              |     |          |                        |              |                         |           |              |                          |                         |              |
| RVD/ACP (+)             | 65  | 65.2 % (43/66)  | --                     | 33.3 % (22/66)  | 89.4 % (59/66)  | 169 (63) | 7 (3)        | 21 (5)                   | 34 (18)                  | LVEF < 40% |
| RVD/ACP (-)             | 62  | 61.3 % (103/168) | --                     | 32.7 % (55/168) | 88.1 % (148/168) | 172 (69) | 6 (3)        | 21 (2)                   | 29 (12)                  | LVEF < 40% |
| Bonizzoli / 2018        |     |          |                        |              |                         |           |              |                          |                         |              |
| RVD/ACP (+)             | 58  | 53.3 % (16/30)  | --                     | --           | 100% (3/3)  | 107 †      | 12.7 †       | --                       | --                       | 54.9% †     |
| RVD/ACP (-)             |     |          |                        |              |                         |           |              |                          |                         |              |

* The numbers were described for patients with only ACP or without ACP and PFO (Patients with only PFO or with PFO and ACP were excluded).

**: The value was reported as median with interquartile range.

***: The summation of each number did not fit the reported total number.

†: The standard deviation could not be calculated.

††: The numbers and percentages are per total population included in the study but not all patients were evaluated for RVD/ACP. Therefore, the total numbers actually analyzed number of patients.
Authors | Age | Male (%) | Fluid in 24 hours (ml) | Vasopressors | Mechanical ventilation | P/F ratio | PEEP (cmH$_2$O) | Plateau pressure (cmH$_2$O) | Compliance (mL/cmH$_2$O) | LV function | $\hat{S}$
---|---|---|---|---|---|---|---|---|---|---|---

*: The numbers were described for patients with only ACP or without ACP and PFO (Patients with only PFO or with PFO and ACP were excluded).

**: The value was reported as median with interquartile range.

***: The summation of each number did not fit the reported total number.

†: The standard deviation could not be calculated

† †: The numbers and percentages are per total population included in the study but not all patients were evaluated for RVD/ACP. Therefore, the total numbers actually analyzed number of patients.

---

**Table 3**

Newcastle-Ottawa Scale assessment of pooled studies.

| Study | Selection | Comparability | Outcomes | Total |
|---|---|---|---|---|
| Osman / 2009 | * | * | * | 7 |
| Bull / 2010 | * | * | * | 7 |
| Fichet / 2012 | * | * | * | 7 |
| Legras / 2015 | * | * | * | 7 |
| Laazeri / 2016 | * | * | * | 7 |
| Mekontso Dessap / 2016 | * | * | * | 9 |
| See / 2017 | * | * | * | 9 |
| Bonizzoli / 2018 | * | * | * | 7 |
| Zeiton / 2018 | * | * | * | 7 |

†: Although multivariate analysis was performed, it was not for 28-day mortality (it was for 90-day mortality).

---

The mean/median age of included patients ranged from 41 to 62, and 44.4–73% were males. Mean/median Simplified Acute Physiology Score II score ranged from 43–50 (patients with RVD: 47–55, patients without RVD: 43–54). In included population, 98.5% (1,834/1,861), and 55.3% (1,030/1,861) received mechanical ventilation, and vasopressors, respectively. Eight of nine studies reported mean/median positive end-expiratory pressure (PEEP) level (range: 7 to 12.7 cmH$_2$O) and P/F ratio (range: 99–171) when patients were evaluated for RVD. Plateau pressure was reported in 6 studies and it ranged from 21 to 33.6 cmH$_2$O. (Table 2) The definition of RVD used in each study is reported in Table 1.

**Outcomes**

RVD was present in 21.0% (391/1,861) of the cohort. In the pooled meta-analysis of 9 studies, the presence of RVD in patients with ARDS was associated with a significantly higher overall mortality (OR: 1.45, 95%CI: 1.13–1.86, p-value = 0.003, $I^2 = 0$%), as shown in Fig. 2. In subgroup analysis investigating short-term and long-term mortalities, the presence of RVD in patients with ARDS was associated with significantly higher short-term mortality (OR: 1.48, 95%CI: 1.14–1.93, p-value = 0.003, $I^2 = 0$%), while the association was not significant in long-term mortality (OR: 1.24, 95%CI: 0.66–2.33, p-value = 0.003, $I^2 = 0$%), as shown in Supplementary Fig. 2.

In the pooled analysis of 3 studies that investigated adjusted odds ratio of mortality, the presence of RVD was associated with a significantly higher mortality (OR: 1.95, 95%CI: 1.30–2.93, p-value = 0.001, $I^2 = 0$%), as shown in Supplementary Fig. 2. Although Lazzeri et al. reported OR for ICU-mortality using a stepwise regression analysis adjusting for TAPSE < 16mm, we did not include this study in the pooled analysis of studies investigated adjusted OR because this was not a multivariate analysis adjusting for risk factors of ICU-mortality.

We detected no evidence of publication bias when we assessed the funnel plots visually, as shown in Supplementary Fig. 2. We also statistically assessed publication bias using Egger's regression test and found no publication bias (p-value = 0.080).
Discussion

In this systematic review and meta-analysis, that included 1,861 patients with ARDS, RVD was present in 21.0% (391 patients) of the cohort. The presence of RVD in ARDS was associated with a significantly higher risk of overall and short-term mortality.

This systematic review also highlights that RVD in literature was evaluated by different modalities and a multitude of definitions which might account for the wide range (9.5–89.5%) of reported prevalence of RVD in ARDS. The ideal modality for the recognition of RVD in critically ill patients remains inconclusive. The complex anatomy of RV and the challenges of image-acquirement in patients with.[29] However, in most ICUs expertise and access to TEE remains limited, constraining the widespread applicability of TEE as a modality of choice. In addition, as shown in our systematic review, various parameters used to define RVD adds to inconsistency in our understanding of RVD in ARDS. This variability arises from the lack of a standardized definition of RVD in critically ill patients, supporting the acute need for validated criteria for RVD in ARDS with various modalities to better understand the prevalence and impact of RVD in patients with ARDS.

In our study, we demonstrated that RVD in ARDS was associated with increased short-term and overall mortalities. Initial studies [16, 20, 21, 23, 27] were not conclusive in assessing the impact of RVD in ARDS owing to their limited sample size and heterogeneity of the study population. The determinants of higher mortality with RVD in patients with ARDS remain poorly understood. Studies have identified driving pressure ≥ 18 cmH2O, PaCO2 ≥ 48 cmH2O, and P/F ratio < 150 mmHg as independent factors associated with the development of RVD.[21] In some, the compromised right ventricle enters a vicious cycle of hemodynamic compromise from cor-pulmonale, deteriorating organ perfusion and failure culminating into death. The concern for higher mortality with RVD in ARDS has steered experts from the “Lung protective” to the “RV protective” approach in ARDS management. The management entails reducing lung stress by limiting plateau < 27 cm H2O and driving pressure at < 18 cm H2O. Prone position ventilation, an intervention with a mortality benefit in ARDS has also been shown to relieve RV enlargement and septal dyskinesia by reducing PVR.[30, 31] The use of pulmonary vasodilators or inotropic agents may also have a role in reducing PVR in RVD.[32] Venovenous extracorporeal membranous oxygenation or extracorporeal carbon dioxide removal has been shown to unload the RV in patients with ARDS and RVD.[33] In addition, the extracorporeal management facilitates limiting injurious ventilator settings and correcting hypercapnia, factors know to worsen RVD. It still remains unclear if the integration of these interventions in a systematic fashion translates to improved clinical outcomes. A randomized controlled trial with well-defined criteria for the early diagnosis of RVD is warranted to evaluate the effectiveness of the RV-protective strategy.

There are limitations in this study. First, the sample sizes of the included studies were relatively small. However, the results of all included studies were quite consistent and the generalizability of this studies’ finding appears to be robust. Second, the definition and modality used to define RVD were not consistent and this might have affected the result of each study. In addition to inconsistent criteria, the limited information of loading conditions including PEEP, plateau pressure, and fluid balance made it challenging to assess RV function accurately. Future studies evaluating RVD in critically ill patients need to use validated criteria developed in concordance with existing ASE guidelines to ensure consistent reporting of prevalence and outcomes of RVD in this population. Third, only two studies investigated long-term mortality and the association between the presence of RVD and long-term mortality was not significant.[23, 27] In addition to a small number of included patients, this might be also because long-term mortality in patients with ARDS mainly depends on non-modifiable factors such as age or comorbidities while short-term outcome has improved with the development of therapeutic interventions.[34]

Conclusion

In this systematic review and meta-analysis including 1,861 patients with ARDS, the presence of RVD was significantly associated with increased overall and short-term mortality. This result implicates the importance of right ventricle assessments in patients with ARDS.

Abbreviations

list
RV
right ventricle / right ventricular
RVD
right ventricular dysfunction
ARDS
acute respiratory distress syndrome
ICU
intensive care unit
TTE
transthoracic echocardiography
TEE
transesophageal echocardiography
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
OR
odds ratio
CIs
Declarations

Author's Contributions

R.S. and S.D. are equally responsible for the conception of the study design, data collection and analysis, interpretation of the analysis, writing of the draft, and critical revision of the manuscript. M.S. contributed substantially to data collection. W.C. contributed substantially to data analysis and interpretation. P.C., A.D. and S.V. supervised drafting and revision of the manuscript. All authors approved the submission of the final manuscript.

Conflicts of Interest

We declare no competing interests.

Data sharing statement

All data associated with this manuscript are included in the main text and supplementary materials.

Funding

None

Acknowledgement

None

Ethics approval

The following systematic review and meta-analysis was registered in PROSPERO

Consent for publication

All authors consent to publication of manuscript and support material.

References

1. Zhang Z, Spieth PM, Chiumello D, Goyal H, Torres, Antoni, Laffrey JG, Hong Y. Declining Mortality in Patients With Acute Respiratory Distress Syndrome: An Analysis of the Acute Respiratory Distress Syndrome Network Trials. Critical care medicine 2019, 47(3).
2. Zochios V, Parhar K, Tunnicliffe W, Roscoe A, Gao F. The Right Ventricle in ARDS. Chest. 2017;152(1):181–93.
3. Price LC, McAuley DF, Marino PS, Finney SJ, Griffiths MJ, Wort SJ. Pathophysiology of pulmonary hypertension in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2012;302(9):L803–15.
4. Mahmood SS, Pinsky MR. Heart-lung interactions during mechanical ventilation: the basics. Annals of translational medicine. 2018;6(18):349–9.
5. Investigators TE, Coordinators* ES. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization EffectivenessThe ESCAPE Trial. Jama. 2005;294(13):1625–33.
6. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.

7. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P). Syst Rev. 2015;4:1.

8. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama. 2000;283(15):2008–12.

9. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. American journal of respiratory and critical care medicine 1994, 149(3 Pt 1):818–824.

10. Force* TADT. Acute Respiratory Distress Syndrome: The Berlin Definition. Jama. 2012;307(23):2526–33.

11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

13. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867–72.

14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

15. Boissier F, Katsahian S, Razaki Z, Thille AW, Roche-Campo F, Leon R, Vivier E, Brochard L, Vichard-Baron A, Brun-Buisson C, et al. Prevalence and prognosis of cor pulmonale during protective ventilation for acute respiratory distress syndrome. Intensive care medicine. 2013;39(10):1725–33.

16. Bonizzoli M, Cipani S, Lazzeri C, Chiostri M, Ballo P, Sartli A, Peris A. Speckle tracking echocardiography and right ventricle dysfunction in acute respiratory distress syndrome a pilot study. Echocardiography. 2018;35(12):1982–7.

17. Lazzeri C, Bonizzoli M, Cianchi G, Batacchi S, Chiostri M, Peris A. Severity of acute respiratory distress syndrome and echocardiographic findings in clinical practice-an echocardiographic pilot study. Heart Lung. 2020;49(5):622–5.

18. Lazzeri C, Bonizzoli M, Cianchi G, Batacchi S, Chiostri M, Fulceri G, Peris A. Right Ventricular Hypertrophy in Refractory Acute Respiratory Distress Syndrome Treated With Venoextracorporeal Membrane Oxygenation Support. J Cardiothorac Vasc Anesth. 2020;34(6):1441–5.

19. Lazzeri C, Cianchi G, Bonizzoli M, Batacchi S, Terenzi P, Bernardo P, Valente S, Gensini GF, Peris A. Right ventricle dilation as a prognostic factor in refractory acute respiratory distress syndrome requiring veno-venous extracorporeal membrane oxygenation. Minerva Anestesiol. 2016;82(10):1043–9.

20. Legras A, Caille A, Begot E, Lhéritier G, Lherm T, Mathonnet A, Frat JP, Courte A, Martin-Lefèvre L, Gouëllo JP, et al. Acute respiratory distress syndrome (ARDS)-associated acute cor pulmonale and patent foramen ovale: a multicenter noninvasive hemodynamic study. Crit Care (London England). 2015;19(1):174.

21. Mekontso Dessap A, Boissier F, Charron C, Bégot E, Repessé X, Legras A, Brun-Buisson C, Vignon P, Vichard-Baron A. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive care medicine. 2016;42(5):862–70.

22. Namendys-Silva SA, Santos-Martínez LE, Pulido T, Rivero-Sigarroa E, Baltazar-Torres JA, Domínguez-Cherit G, Sandoval J. Pulmonary hypertension due to acute respiratory distress syndrome: a pilot study. Braz J Med Biol Res. 2014;47(10):904–10.

23. Osman D, Monnet X, Castelain V, Anguel N, Warszawski J, Touboul JL, Richard C. Incidence and prognostic value of right ventricular failure in acute respiratory distress syndrome. Intensive care medicine. 2009;35(1):69–76.

24. See KC, Ng J, Slow WT, Ong V, Phua J. Frequency and prognostic impact of basic critical care echocardiography abnormalities in patients with acute respiratory distress syndrome. Ann Intensive Care. 2017;7(1):120.

25. Vieillard-Baron A, Schmitt JM, Augarde R, Fellahi JL, Prin S, Page B, Beauchet A, Jardin F. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Critical care medicine. 2001;29(8):1551–5.

26. Zeiton TM, Elsayed HEM, Hassan OS, Sarhan AM. Clinical risk score for the diagnosis of acute cor pulmonale in acute respiratory distress syndrome. The Egyptian Journal of Chest Diseases Tuberculosis. 2018;67(2):146–55.

27. Bull TM, Clark B, McCann K, Moss M. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. Am J Respir Crit Care Med. 2010;182(9):1123–8.

28. Fichet J, Moreau L, Geneè O, Legras A, Mercier E, Garot D, Dequin PF, Perrotin D. Feasibility of right ventricular longitudinal systolic function evaluation with transthoracic echocardiographic indices derived from tricuspid annular motion: a preliminary study in acute respiratory distress syndrome. Echocardiography. 2012;29(5):513–21.

29. Lhéritier G, Legras A, Caille A, Lherm T, Mathonnet A, Frat JP, Courte A, Martín-Lefèvre L, Gouëllo JP, Amiel JB, et al. Prevalence and prognostic value of acute cor pulmonale and patent foramen ovale in ventilated patients with early acute respiratory distress syndrome: a multicenter study. Intensive care medicine. 2013;39(10):1734–42.

30. Jozwiaik M, Touboul JL, Anguel N, Persichini R, Silva S, Chemla D, Richard C, Monnet X. Beneficial hemodynamic effects of prone positioning in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2013;188(12):1428–33.

31. Guérin C, Reignier J, Richard J-C, Beuret P, Gacouin A, Boulin T, Mercier E, Badet M, Mercat A, Baudin O, et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2013;368(23):2159–68.

32. Ventetuolo CE, Klinger JR. Management of acute right ventricular failure in the intensive care unit. Ann Am Thorac Soc. 2014;11(5):811–22.

33. Reis Miranda D, van Thiel R, Brodie D, Bakker J. Right ventricular unloading after initiation of venovenous extracorporeal membrane oxygenation. Am J Respir Crit Care Med. 2015;191(3):346–8.
34. Chiumello D, Coppola S, Froio S, Gotti M. What’s Next After ARDS: Long-Term Outcomes. Respir Care. 2016;61(5):689–99.